77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
70 citations,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
67 citations,
January 2022 in “Theranostics” Advanced nanocarrier and microneedle drug delivery methods are more effective, safer, and less invasive for treating skin diseases.
67 citations,
December 2019 in “PloS one” Beta-caryophyllene helps improve wound healing in mice, especially in females.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
63 citations,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
60 citations,
March 2011 in “Proceedings of the National Academy of Sciences of the United States of America” RANK-RANKL signaling is essential for hair growth and skin health.
56 citations,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
53 citations,
November 2006 in “Journal of Endocrinology” Prolactin slows down hair growth in mice.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
51 citations,
July 2010 in “Trends in Endocrinology and Metabolism” Prolactin may play a significant role in skin and hair health and could be a target for treating skin and hair disorders.
50 citations,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
50 citations,
February 2018 in “Biomedicine & pharmacotherapy” Ginseng may help treat cancer and reduce treatment side effects, but more research is needed.
47 citations,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
47 citations,
March 2019 in “Journal of immunology research” Valproic Acid could potentially be used to treat immune-related conditions due to its ability to modify immune cell functions.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
40 citations,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
38 citations,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
37 citations,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
36 citations,
November 2009 in “Journal of Investigative Dermatology” Prolactin may affect hair growth differently based on gender and scalp area.
32 citations,
April 2019 in “JAAD case reports” JAK inhibitors helped treat hair loss in two people with Down syndrome.
32 citations,
April 2016 in “Journal of Investigative Dermatology” STAT5 activation is crucial for starting the hair growth phase.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
28 citations,
October 2019 in “Seminars in Cell & Developmental Biology” Hair can regrow in large wounds through a process similar to how hair forms in embryos, and understanding this could lead to new treatments for hair loss or scarring.
26 citations,
June 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Regenerative therapies show promise for treating vitiligo and alopecia areata.